Status:
UNKNOWN
Oseltamivir Versus Paracetamol for Influenza-like Illness During the Influenza Season
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Influenza
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Parallel group, investigator initiated, 1:1, open-label, non-inferiority randomized controlled trial, aiming to show that paracetamol is non-inferior to oseltamivir among patients with serious acute r...
Detailed Description
Study setting: a single tertiary hospital, containing 1,000 beds. Intervention: best medical care and oral oseltamivir 75 mg twice daily for five days. Control: best medical care and oral paracetamol...
Eligibility Criteria
Inclusion
- Age ≥18 years
- admitted to the hospital during the influenza "high season" with SARI.
Exclusion
- Severe disease on admission, defined as any of the following: patients deemed to require intensive care immediately upon admission, a high probability of imminent respiratory failure as judged by the ER physician.
- Pregnancy.
- Severe immunosuppression including: Acquired immunodeficiency syndrome (AIDS) or Human immunodeficiency virus (HIV) with unknown CD4 or with CD4 \< 200/mL, solid organ and stem cell transplant recipients, or neutrophil count of less than 100 per µliter.
- Patients with decompensated cirrhosis.
- Patients discharged home from the ER.
- Patients unable to sign informed consent with no legal guardian.
- Patients who received at least 2 doses of oseltamivir prior to randomization.
Key Trial Info
Start Date :
February 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
436 Patients enrolled
Trial Details
Trial ID
NCT03754686
Start Date
February 10 2019
End Date
July 1 2022
Last Update
January 30 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.